Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)

Clinical trial NCT07530796 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07530796
Sponsor: Rare Trait Hope
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Aspartylglucosaminuria Aspartylglucosamidase (AGA) Deficiency

Start date: 2026-05-01
Primary completion: 2029-05-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.